schliessen

Filtern

 

Bibliotheken

Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects

Summary The promise of combination HIV prevention—the application of multiple HIV prevention interventions to maximise population-level effects—has never been greater. However, to succeed in achieving significant reductions in HIV incidence, an additional concept needs to be considered: combination... Full description

Journal Title: The Lancet infectious diseases 2013, Vol.13 (1), p.65-76
Main Author: Chang, Larry W, Dr
Other Authors: Serwadda, David, Prof , Quinn, Thomas C, Prof , Wawer, Maria J, Prof , Gray, Ronald H, Prof , Reynolds, Steven J, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Elsevier Ltd
ID: ISSN: 1473-3099
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1458525973
title: Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects
format: Article
creator:
  • Chang, Larry W, Dr
  • Serwadda, David, Prof
  • Quinn, Thomas C, Prof
  • Wawer, Maria J, Prof
  • Gray, Ronald H, Prof
  • Reynolds, Steven J, MD
subjects:
  • Anti-HIV Agents - therapeutic use
  • Antiviral agents
  • Biological and medical sciences
  • Circumcision
  • Clinical trials
  • Clinical Trials as Topic
  • Counseling
  • Epidemics - prevention & control
  • HIV (Viruses)
  • HIV - isolation & purification
  • HIV Infections - diagnosis
  • HIV Infections - drug therapy
  • HIV Infections - epidemiology
  • HIV Infections - prevention & control
  • Human viral diseases
  • Humans
  • Immunodeficiencies
  • Immunodeficiencies. Immunoglobulinopathies
  • Immunopathology
  • Infectious Disease
  • Infectious diseases
  • Medical colleges
  • Medical sciences
  • Prevention
  • Public health
  • Sexually transmitted diseases
  • Viral diseases
  • Viral diseases of the lymphoid tissue and the blood. Aids
ispartof: The Lancet infectious diseases, 2013, Vol.13 (1), p.65-76
description: Summary The promise of combination HIV prevention—the application of multiple HIV prevention interventions to maximise population-level effects—has never been greater. However, to succeed in achieving significant reductions in HIV incidence, an additional concept needs to be considered: combination implementation. Combination implementation for HIV prevention is the pragmatic, localised application of evidence-based strategies to enable high sustained uptake and quality of interventions for prevention of HIV. In this Review, we explore diverse implementation strategies including HIV testing and counselling models, task shifting, linkage to and retention in care, antiretroviral therapy support, behaviour change, demand creation, and structural interventions, and discusses how they could be used to complement HIV prevention efforts such as medical male circumcision and treatment as prevention. HIV prevention and treatment have arrived at a pivotal moment when combination efforts might result in substantial enough population-level effects to reverse the epidemic and drive towards elimination of HIV. Only through careful consideration of how to implement and operationalise HIV prevention interventions will the HIV community be able to move from clinical trial evidence to population-level effects.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1473-3099
fulltext: fulltext
issn:
  • 1473-3099
  • 1474-4457
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6337395
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1458525973
sourceformatXML
sourcesystemPC
galeidA312902847
sourcerecordidA312902847
originalsourceidFETCH-LOGICAL-1611t-ed38b56a2966d219bb9e43f07102eb909f617174f51dc2f2688c24df0401652e3
addsrcrecordideNqFkm1r1EAQx4Motp5-BCUgQgVT9ymbxBdKOdQWCr7w4e2SbGbPrclu3E0O-u2dXK6eLUIJTLKT3_yZ2fknyXNKTimh8u1XKgqecVJVJ5S9LgjDk3yQHGNaZELkxcPd94IcJU9ivCKEFpSIx8kR4ywvMBwnbu37xrp6tN6lth866MGNy9H4kJ5f_EiHAFtMYupd2vutdZvUBN-nurPO6rpLx2Axwta24DSko08HP0zdTiXrsBh_GgN6jE-TR6buIjzbv1fJ908fv63Ps8svny_WZ5cZlZSOGbS8bHJZs0rKltGqaSoQ3BBsn0FTkcpIHKUQJqetZobJstRMtIYIvJqcAV8lJ4vuEPzvCeKoehs1dF3twE9RUZGXOcurgt-P4s0KyipGEH15B73yU3A4CFK8Ejllkh-oTd2Bss74MdR6FlVnHIUIK3Evq-T0PxQ-LfRWewfGYv5WwZt_CpopWgcRQ7Sbn2Pc1FOMt_F8wXXwMQYwagi2r8O1okTNDlI7B6nZHti92jlISax7sZ9xanpo_1bdWAaBV3ugjrh8E2qnbTxwsmAlLSlyHxYOcM9bC0FFbWd_tDagFVTr7b2tvL-jcOO4X3AN8XD3KjJFFpFZAzc2K0j-B0ob9Ck
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1239451263
display
typearticle
titleCombination implementation for HIV prevention: moving from clinical trial evidence to population-level effects
sourceAlma/SFX Local Collection
creatorChang, Larry W, Dr ; Serwadda, David, Prof ; Quinn, Thomas C, Prof ; Wawer, Maria J, Prof ; Gray, Ronald H, Prof ; Reynolds, Steven J, MD
creatorcontribChang, Larry W, Dr ; Serwadda, David, Prof ; Quinn, Thomas C, Prof ; Wawer, Maria J, Prof ; Gray, Ronald H, Prof ; Reynolds, Steven J, MD
descriptionSummary The promise of combination HIV prevention—the application of multiple HIV prevention interventions to maximise population-level effects—has never been greater. However, to succeed in achieving significant reductions in HIV incidence, an additional concept needs to be considered: combination implementation. Combination implementation for HIV prevention is the pragmatic, localised application of evidence-based strategies to enable high sustained uptake and quality of interventions for prevention of HIV. In this Review, we explore diverse implementation strategies including HIV testing and counselling models, task shifting, linkage to and retention in care, antiretroviral therapy support, behaviour change, demand creation, and structural interventions, and discusses how they could be used to complement HIV prevention efforts such as medical male circumcision and treatment as prevention. HIV prevention and treatment have arrived at a pivotal moment when combination efforts might result in substantial enough population-level effects to reverse the epidemic and drive towards elimination of HIV. Only through careful consideration of how to implement and operationalise HIV prevention interventions will the HIV community be able to move from clinical trial evidence to population-level effects.
identifier
0ISSN: 1473-3099
1EISSN: 1474-4457
2DOI: 10.1016/S1473-3099(12)70273-6
3PMID: 23257232
4CODEN: LANCAO
languageeng
publisherLondon: Elsevier Ltd
subjectAnti-HIV Agents - therapeutic use ; Antiviral agents ; Biological and medical sciences ; Circumcision ; Clinical trials ; Clinical Trials as Topic ; Counseling ; Epidemics - prevention & control ; HIV (Viruses) ; HIV - isolation & purification ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - prevention & control ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious Disease ; Infectious diseases ; Medical colleges ; Medical sciences ; Prevention ; Public health ; Sexually transmitted diseases ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids
ispartofThe Lancet infectious diseases, 2013, Vol.13 (1), p.65-76
rights
0Elsevier Ltd
12013 Elsevier Ltd
22014 INIST-CNRS
3Copyright © 2013 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2013 Elsevier B.V.
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1611t-ed38b56a2966d219bb9e43f07102eb909f617174f51dc2f2688c24df0401652e3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26728181$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23257232$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Chang, Larry W, Dr
1Serwadda, David, Prof
2Quinn, Thomas C, Prof
3Wawer, Maria J, Prof
4Gray, Ronald H, Prof
5Reynolds, Steven J, MD
title
0Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects
1The Lancet infectious diseases
addtitleLancet Infect Dis
descriptionSummary The promise of combination HIV prevention—the application of multiple HIV prevention interventions to maximise population-level effects—has never been greater. However, to succeed in achieving significant reductions in HIV incidence, an additional concept needs to be considered: combination implementation. Combination implementation for HIV prevention is the pragmatic, localised application of evidence-based strategies to enable high sustained uptake and quality of interventions for prevention of HIV. In this Review, we explore diverse implementation strategies including HIV testing and counselling models, task shifting, linkage to and retention in care, antiretroviral therapy support, behaviour change, demand creation, and structural interventions, and discusses how they could be used to complement HIV prevention efforts such as medical male circumcision and treatment as prevention. HIV prevention and treatment have arrived at a pivotal moment when combination efforts might result in substantial enough population-level effects to reverse the epidemic and drive towards elimination of HIV. Only through careful consideration of how to implement and operationalise HIV prevention interventions will the HIV community be able to move from clinical trial evidence to population-level effects.
subject
0Anti-HIV Agents - therapeutic use
1Antiviral agents
2Biological and medical sciences
3Circumcision
4Clinical trials
5Clinical Trials as Topic
6Counseling
7Epidemics - prevention & control
8HIV (Viruses)
9HIV - isolation & purification
10HIV Infections - diagnosis
11HIV Infections - drug therapy
12HIV Infections - epidemiology
13HIV Infections - prevention & control
14Human viral diseases
15Humans
16Immunodeficiencies
17Immunodeficiencies. Immunoglobulinopathies
18Immunopathology
19Infectious Disease
20Infectious diseases
21Medical colleges
22Medical sciences
23Prevention
24Public health
25Sexually transmitted diseases
26Viral diseases
27Viral diseases of the lymphoid tissue and the blood. Aids
issn
01473-3099
11474-4457
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNqFkm1r1EAQx4Motp5-BCUgQgVT9ymbxBdKOdQWCr7w4e2SbGbPrclu3E0O-u2dXK6eLUIJTLKT3_yZ2fknyXNKTimh8u1XKgqecVJVJ5S9LgjDk3yQHGNaZELkxcPd94IcJU9ivCKEFpSIx8kR4ywvMBwnbu37xrp6tN6lth866MGNy9H4kJ5f_EiHAFtMYupd2vutdZvUBN-nurPO6rpLx2Axwta24DSko08HP0zdTiXrsBh_GgN6jE-TR6buIjzbv1fJ908fv63Ps8svny_WZ5cZlZSOGbS8bHJZs0rKltGqaSoQ3BBsn0FTkcpIHKUQJqetZobJstRMtIYIvJqcAV8lJ4vuEPzvCeKoehs1dF3twE9RUZGXOcurgt-P4s0KyipGEH15B73yU3A4CFK8Ejllkh-oTd2Bss74MdR6FlVnHIUIK3Evq-T0PxQ-LfRWewfGYv5WwZt_CpopWgcRQ7Sbn2Pc1FOMt_F8wXXwMQYwagi2r8O1okTNDlI7B6nZHti92jlISax7sZ9xanpo_1bdWAaBV3ugjrh8E2qnbTxwsmAlLSlyHxYOcM9bC0FFbWd_tDagFVTr7b2tvL-jcOO4X3AN8XD3KjJFFpFZAzc2K0j-B0ob9Ck
startdate2013
enddate2013
creator
0Chang, Larry W, Dr
1Serwadda, David, Prof
2Quinn, Thomas C, Prof
3Wawer, Maria J, Prof
4Gray, Ronald H, Prof
5Reynolds, Steven J, MD
general
0Elsevier Ltd
1Lancet Publishing Group
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TZ
113V.
127QL
137RV
147U9
157X7
167XB
1788E
188AO
198C1
208C2
218FI
228FJ
238FK
24ABUWG
25BENPR
26C1K
27FYUFA
28GHDGH
29H94
30K9.
31KB0
32M0S
33M1P
34M7N
35NAPCQ
36PQEST
37PQQKQ
38PQUKI
397X8
407T2
417U2
sort
creationdate2013
titleCombination implementation for HIV prevention: moving from clinical trial evidence to population-level effects
authorChang, Larry W, Dr ; Serwadda, David, Prof ; Quinn, Thomas C, Prof ; Wawer, Maria J, Prof ; Gray, Ronald H, Prof ; Reynolds, Steven J, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1611t-ed38b56a2966d219bb9e43f07102eb909f617174f51dc2f2688c24df0401652e3
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Anti-HIV Agents - therapeutic use
1Antiviral agents
2Biological and medical sciences
3Circumcision
4Clinical trials
5Clinical Trials as Topic
6Counseling
7Epidemics - prevention & control
8HIV (Viruses)
9HIV - isolation & purification
10HIV Infections - diagnosis
11HIV Infections - drug therapy
12HIV Infections - epidemiology
13HIV Infections - prevention & control
14Human viral diseases
15Humans
16Immunodeficiencies
17Immunodeficiencies. Immunoglobulinopathies
18Immunopathology
19Infectious Disease
20Infectious diseases
21Medical colleges
22Medical sciences
23Prevention
24Public health
25Sexually transmitted diseases
26Viral diseases
27Viral diseases of the lymphoid tissue and the blood. Aids
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Chang, Larry W, Dr
1Serwadda, David, Prof
2Quinn, Thomas C, Prof
3Wawer, Maria J, Prof
4Gray, Ronald H, Prof
5Reynolds, Steven J, MD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9Pharma and Biotech Premium PRO
10ProQuest Central (Corporate)
11Bacteriology Abstracts (Microbiology B)
12Nursing & Allied Health Database
13Virology and AIDS Abstracts
14Health & Medical Collection
15ProQuest Central (purchase pre-March 2016)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Lancet Titles
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23ProQuest Central (Alumni Edition)
24ProQuest Central
25Environmental Sciences and Pollution Management
26Health Research Premium Collection
27Health Research Premium Collection (Alumni)
28AIDS and Cancer Research Abstracts
29ProQuest Health & Medical Complete (Alumni)
30Nursing & Allied Health Database (Alumni Edition)
31Health & Medical Collection (Alumni Edition)
32Medical Database
33Algology Mycology and Protozoology Abstracts (Microbiology C)
34Nursing & Allied Health Premium
35ProQuest One Academic Eastern Edition
36ProQuest One Academic
37ProQuest One Academic UKI Edition
38MEDLINE - Academic
39Health and Safety Science Abstracts (Full archive)
40Safety Science and Risk
jtitleThe Lancet infectious diseases
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Chang, Larry W, Dr
1Serwadda, David, Prof
2Quinn, Thomas C, Prof
3Wawer, Maria J, Prof
4Gray, Ronald H, Prof
5Reynolds, Steven J, MD
formatjournal
genrearticle
ristypeJOUR
atitleCombination implementation for HIV prevention: moving from clinical trial evidence to population-level effects
jtitleThe Lancet infectious diseases
addtitleLancet Infect Dis
date2013
risdate2013
volume13
issue1
spage65
epage76
pages65-76
issn1473-3099
eissn1474-4457
codenLANCAO
abstractSummary The promise of combination HIV prevention—the application of multiple HIV prevention interventions to maximise population-level effects—has never been greater. However, to succeed in achieving significant reductions in HIV incidence, an additional concept needs to be considered: combination implementation. Combination implementation for HIV prevention is the pragmatic, localised application of evidence-based strategies to enable high sustained uptake and quality of interventions for prevention of HIV. In this Review, we explore diverse implementation strategies including HIV testing and counselling models, task shifting, linkage to and retention in care, antiretroviral therapy support, behaviour change, demand creation, and structural interventions, and discusses how they could be used to complement HIV prevention efforts such as medical male circumcision and treatment as prevention. HIV prevention and treatment have arrived at a pivotal moment when combination efforts might result in substantial enough population-level effects to reverse the epidemic and drive towards elimination of HIV. Only through careful consideration of how to implement and operationalise HIV prevention interventions will the HIV community be able to move from clinical trial evidence to population-level effects.
copLondon
pubElsevier Ltd
pmid23257232
doi10.1016/S1473-3099(12)70273-6
oafree_for_read